Novartis China Breaks Ground on First Radioligand Therapy Manufacturing Facility in Haiyan, Strengthening Global RLT Supply Chain

On July 2, Novartis China's radiopharmaceutical production project held a groundbreaking ceremony in Haiyan, Zhejiang, officially launching the construction of the project.This is Novartis' first radioligand therapy production base in China., Expanding the production and supply capabilities of innovative radioligand therapies in China and globally, supporting the clinical application and development of China's healthcare industry, further fulfilling Novartis' commitment to deepen its presence in the Chinese market, and bringing more efficient and safer innovative therapies to more patients in China.

The radiopharmaceutical production project of Novartis China is the second innovative drug production base of Novartis in China, located in the nuclear technology application (isotope) industrial park in Haiyan County, Zhejiang Province, with an estimated total investment of 600 million RMB. From design to construction, it adopts advanced technologies and processes in the industry, adhering to the strictest safety requirements and the highest quality standards, and plans to produce internationally advanced radioligand therapy drugs. Subject to obtaining necessary regulatory approvals and permits,Novartis China's Radiopharmaceutical Production Project Expected to Be Completed and Operational by the End of 2026, which will be able to mass-produce innovative drugs required for precise tumor treatment for Chinese patients at that time.

Radioligand therapy aims to redefine the standard of care for patients with various types of cancer.Radioligand therapy is an innovative conjugate drug that combines radionuclides with specific ligands targeting tumors, acting like "tumor-targeting missiles" with the ability to precisely kill tumor cells. It achieves accurate and efficient elimination of cancer cells while, due to its moderate radiation range, minimizing damage to healthy cells, enabling safe, targeted, and systemic precision treatment of tumors.

NovartisNovartisShreeram Aradhye, President of Drug Development and Chief Medical Officer, introduced:

Radioligand Therapy, along with Chemotherapy, Biologic Therapy, Gene and Cell Therapy, and xRNA Therapy, is one of the five key technology platforms that Novartis focuses on. In March 2022, an innovative drug from Novartis targeting Radioligand Therapy was approved by the U.S. Food and Drug Administration for the treatment of patients with metastatic castration-resistant prostate cancer who are positive for prostate-specific membrane antigen (PSMA) and have progressed after previous treatment with androgen receptor pathway inhibitors and taxane chemotherapy. In December 2022, this innovative drug received approval in the European Union. Multiple multi-center clinical studies on this therapy have been initiated in China, but it has not yet been approved domestically. As of 2023, Novartis has several radioligand therapy-related products under development globally., expanding to other solid tumors。

The radiopharmaceuticals industry in China has become a strategically emerging industry supported by the national government, with numerous favorable policies introduced successively. Novartis has accumulated highly specialized expertise in the research and development, production, clinical application, as well as interdisciplinary and cross-industry cooperation in the field of radioligand therapy. After the completion of Novartis China's Haiyan radiopharmaceutical production base, it will further enhance Novartis’ global layout of radioligand therapy together with the existing production bases in Indianapolis and Millburn in the United States, Zaragoza in Spain, and Ivrea in Italy, meeting the growing demand of patients worldwide.

Innovation is the cornerstone of Novartis, and talent is the key to innovation. The future is here. As Novartis continues to cultivate and experience rapid growth in radioligand therapy, it is also building a talent pipeline in related fields and creating the best radioligand therapy team. Talent will achieve synchronized acceleration with innovative businesses.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.